All In Biotech

Drug Trial Radar · NCT02858310

E7 TCR T Cells for Human Papillomavirus-Associated Cancers

A Phase I/II Trial of T Cell Receptor Gene Therapy Targeting HPV-16 E7 for HPV-Associated Cancers

Last checked: Nov 19, 2026Latest source record: Mar 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

224

Actual

Start

Jan 27, 2017

Primary completion

Jul 2, 2025

Study completion Jul 2, 2025

Sponsor

Sponsor type
NIH
First posted
Aug 8, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 120 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Background: Human papillomavirus (HPV) can cause cervical, throat, anal, and genital cancers. Cancers caused by HPV have an HPV protein called E7 inside of their cells. In this new therapy, researchers take a person's blood, remove certain white blood cells, and insert genes that make them to target cancer cells that have the E7 protein. The genetically changed cells, called E7 T cell receptor (TCR) cells, are then given back to the person to fight the cancer. Researchers want to see if this can help people. Objective: To determine a safe dose and efficacy of E7 TCR cells and whether these cells can help patients. Eligibility: Adults ages 18 and older with an HPV-16-associated cancer, including cervical, vulvar, vaginal, penile, anal, or oropharyngeal. Design: Participants will list all their medicines. Participants will have many screening tests, including imaging procedures, heart and lung tests, and lab tests. They will have a large catheter inserted into a vein. Participants will have leukapheresis. Blood will be removed through a needle in the arm. A machine separates the white blood cells. The rest of the blood is returned through a needle in the other arm. The cells will be changed in the lab. Participants will stay in the hospital. Over several days, they will get: Chemotherapy drugs E7 TCR cells Shots or injections to stimulate the cells Participants will be monitored in the hospital up to 12 days. They will get support medicine and have blood and lab tests. Participants will have a clinic visit about 40 days after cell infusion. They will have a physical exam, blood work, scans, and maybe x-rays. Participants will have many follow-up visits with the same procedures. At some visits, they may undergo leukapheresis. Participants will be followed for 15 years.

Conditions

  • Papillomavirus Infections
  • Cervical Intraepithelial Neoplasia
  • Carcinoma In Situ
  • Vulvar Neoplasms
  • Vulvar Diseases

Interventions

  • E7 TCR cellsBiological

    T cells genetically engineered with a T cell receptor (TCR) targeting human papillomavirus (HPV -16 E7 (E7 TCR) that display specific reactivity against human leukocyte antigen (HLA-A2+, HPV-16+ target cells.

  • AldesleukinDrug

    Following cell infusion, the patient receives high-dose bolus aldesleukin, which is dosed to individual patient tolerance. Aldesleukin improves the survival of E7 T cell receptor (TCR) cells after infusion.

  • FludarabineDrug

    Part of the non-myeloablative lymphocyte-depleting preparative regimen.

  • CyclophosphamideDrug

    Part of the non-myeloablative lymphocyte-depleting preparative regimen.

  • EKGDiagnostic test

    Screening/Baseline. Follow-up (end of treatment).

  • BiopsyProcedure

    Screening/Baseline. Following treatment (6 weeks post treatment preferred) and at disease progression only.

  • Chest CT and MRI or PETDiagnostic test

    Screening/Baseline. Follow-up (end of treatment). 40 days (+/- 2 weeks) after cell infusion; additional visits as indicated.

  • PFTDiagnostic test

    Screening/Baseline.

  • GranisetronDrug

    Supportive medication for nausea/vomiting/anorexia. 0.01 mg/kg intravenous (IV) every(q) day as needed (prn).

  • OndansetronDrug

    Supportive medication for nausea/vomiting/anorexia. Ondansetron 10mg intravenous (IV) every(q) 8 hours(hr) as needed (prn).

  • DroperidolDrug

    Supportive medication for nausea/vomiting/anorexia. 1mg intravenous (IV) at 4-6 hours(h) as needed (prn).

  • ProchlorperazineDrug

    Supportive medication for nausea/vomiting/anorexia. 25mg per rectum (PR) as needed (prn) or 10mg intravenous (IV) every(q) 6hours(h) prn.

  • Diphenoxylate HCLDrug

    Supportive medication for diarrhea. 2.5mg by mouth (po) every(q) 3 hours(h) as needed (prn).

  • Atropine sulfateDrug

    Supportive medication for diarrhea. 25mcg by mouth (po) every(q) 3 hours(h) as needed (prn).

  • Codeine sulfateDrug

    Supportive medication for diarrhea. 30-60mg by mouth (po) every(q) 4 hours(h) as needed (prn).

  • LoperamideDrug

    Supportive medication for diarrhea. 2mg by mouth (po) every(q) 3 hours(h) as needed (prn).

  • IndomethacinDrug

    Supportive medication for fever. 50-75mg by mouth (po) every(q) 8 hours(h).

  • AcetaminophenDrug

    Supportive medication for fever. 650mg by mouth (po) every 4 hours (q) 4hr.

  • Diphenhydramine HCLDrug

    Supportive medication for pruritis. 25-50mg by mouth (po) every 4 hours (q) 4hr as needed (prn).

  • Hydroxyzine HCLDrug

    Supportive medication for pruritis. 10-20mg by mouth (po) every 6 hours(h), as needed (prn).

  • MeperidineDrug

    Supportive medication for chills. 25-50mg intravenous (IV) every 1 hour (q1hr), as needed (prn).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase II: Overall Response Rate Partial Response + Complete Response (PR +CR)Time frame: At 12 weeks, every 3 months x 3, and every 6 months for approximately 5 years
  2. Phase I: Number of Dose Limiting Toxicities (DLT)Time frame: From the day of cell infusion (Day 0) to Day +30

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • National Institutes of Health Clinical Center

    Bethesda, Maryland

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.